ABSTRACT: Introduction: Exercise-associated muscle cramping (EAMC) is a poorly understood problem that is neuromuscular in origin. Ingestion of transient receptor potential (TRP) channel agonists has been efficacious in attenuating electrically induced muscle cramps. This study examines the effect of TRP agonist ingestion on voluntarily induced EAMC and motor function. Methods: Study 1: Thirty-nine participants completed 2 trials after ingesting TRP agonist-containing active treatment (A), or vehicle (V) control. Cramping in the triceps surae muscle was induced via voluntary isometric contraction. Study 2: After ingesting A or V, 31 participants performed kinematic and psychomotor tests of manual dexterity. Results: A increased precramp contraction duration (A, 36.9 6 4.1 s; V, 27.8 6 3.1 s), decreased cramp EMG area under the curve (A, 37.3 6 7.7 %EMG max Ás; V, 77.2 6 17.7 %EMG max Ás), increased contraction force to produce the cramp (A, 13.8 6 1.8 kg; V, 9.9 6 1.6 kg), and decreased postcramp soreness (A, 4.1 6 0.3 arbitrary units (a.u.); V, 4.7 6 0.3 a.u.). Kinematic and psychomotor tests were not affected. Discussion: TRP agonist ingestion attenuated EAMC characteristics without affecting motor function.
(EAMC) are common, their etiology is not fully understood. Common theories are that EAMCs are caused by dehydration, altered plasma electrolyte concentrations, or a-motor neuron hyperexcitability. 1 Neither hydration nor serum electrolyte status varies between crampers and noncrampers during endurance events. 2, 3 Hypohydration does not change cramp threshold frequency in electrically induced muscle cramps. 4 These findings suggest that dehydration does not initiate cramping but do not rule out a role in muscle cramp triggering or susceptibility. Dehydration and electrolyte depletion may increase the rate of muscle fatigue, causing cramping to develop more quickly during exercise. 1 Stretching relieves muscle cramps without altering hydration or electrolyte status, [5] [6] [7] demonstrating that restoring electrolyte and fluid balance is not requisite for alleviating EAMC. It has been proposed that a neural mechanism linked to a-motor neuron hyperexcitability mediates EAMC and almost certainly involves the final common pathway.
Transient receptor potential (TRP) channels are involved in sensory transduction of temperature and chemicals. 8, 9 Among the members of the TRP superfamily, activation of different subtypes produces diverse physiological responses. TRP vanilloid 1 (TRPV1) opens in response to high temperature (>428C) and capsaicin, 10 a compound that elicits hot/spicy sensations. TRPV1 is expressed in C and A delta (Ad)-sensory nerve fibers in most tissues. 10 TRP ankyrin 1 (TRPA1) opens in response to ginger 11 and cinnamaldehyde, 11 which evokes the flavor of cinnamon. TRPA1 is colocated primarily on C and Ad-nerve fibers that express TRPV1. 12 Both TRPV1 and TRPA1 channels are expressed in the mucosal linings of the mouth, oropharynx, esophagus, and stomach [13] [14] [15] and on spinal nerves. 16, 17 Strong excitatory sensory stimuli can elicit generalized depression of efferent neural output. 18 For example, stimulation of oropharyngeal chemoreceptors with citric acid decreased gastric myoelectrical activity. 19 Given the role of TRP channels in sensory transduction, potent TRP channel stimulation has the potential to decrease efferent neural function, including that of a-motor neurons innervating skeletal muscle, as demonstrated by Mandadi et al., 20 who showed that treatment of spinal afferents with capsaicin decreased spinal motor nerve output. Given the widespread expression of TRP channels in the mouth and the digestive tract, orally administered TRP channel agonists may decrease excitability of a-motor neurons. This hypothesized mechanism of action is similar to other established pathways in which stimulation of the vagus and glossopharyngeal nerves sends afferent signals to the nucleus tractus solitarius, which can subsequently alter efferent motor output. 21 Given that EAMC is likely neural in nature, stimulation of oral sensory nerves with TRP agonists has the potential to decrease a-motor neuron hyperexcitability and delay or attenuate EAMC. Short et al. 22 showed a threefold reduction in electrically induced muscle cramp intensity in the flexor hallucis brevis after TRP agonist ingestion, and Rosen et al. 23 found that TRP agonists attenuated electrically induced muscle cramps in the abductor hallucis brevis. Although electrically induced cramps are highly reproducible, an exercise-based model of EAMC better reflects realworld conditions. This study assesses (1) the effect of oral TRP channel activators on voluntarily induced muscle cramps and (2) whether potential TRP channel mediated alterations in neural output impair performance of fine psychomotor skills. We hypothesize that activation of oral and upper gastrointestinal TRPV1 and TRPA1 channels attenuate muscle cramps in a selfinduced isometric cramp model, likely by decreasing a-motor neuron hyperexcitability.
MATERIALS AND METHODS
All protocols complied with the Declaration of Helsinki and were approved by the institutional review board at The Pennsylvania State University. Participants provided voluntary written and verbal consent prior to participation in the study. Participants. Participants were young, recreationally active, nonsmokers, and free of neuromuscular disease. All participants reported at least 1 instance of EAMC during the previous year.
Study Design. This is a double blind, randomized, cross-over study. Participants visited the laboratory for 3 familiarization trials during which they ingested a placebo beverage (flavored water) and underwent a protocol to induce muscle cramping (described below). To be included in the randomized study phase, participants had to cramp during the first familiarization trial and during 1 of the subsequent 2 trials. These initial 3 trials served to identify participants with the ability to voluntarily reproduce cramps and to minimize learning effects.
Repeat crampers visited the laboratory on 2 additional occasions, during which they received either the active treatment (A) containing naturally occurring TRP channel activators or a strongly flavored vehicle control (V; drink base without the TRP agonists) in a randomized, counterbalanced order. All trials, including the familiarization trials, were separated by at least 1 but not more than 2 weeks.
Drinks were provided in coded bottles to ensure blinding of the researchers. Researchers involved in data analysis left the room while a research assistant delivered the test beverage to prevent researchers from inadvertently smelling the substances or observing involuntary verbal or physical responses from the participants. Participants were instructed not to divulge information about the taste profile or other characteristics of the beverages to the researchers. Beverage A had a potent spicy profile, whereas beverage V had a strong fruit taste profile.
Voluntary Cramp Model. Participants refrained from vigorous exercise for 24 h and from consuming food, caffeine, or alcohol for 12 h prior to each experiment. Participants were instructed to drink at least six 8-ounce glasses of water the day before each experiment.
After they had arrived at the laboratory, participants consumed 50 mL of beverage. After a participant had finished the beverage, the lower leg of the participant's choice was prepared for electromyography (EMG) electrode placement. EMG signals were recorded with a wired amplifier system (IX-BIO8; iWorx Systems, Dover NH). After the skin had been prepared, 50-mm bipolar, silver-silver chloride, surface electrodes (SKINTACT, Inverness, FL) were placed over the muscle centers of the medial gastrocnemius, lateral gastrocnemius, tibialis anterior, and soleus with an interelectrode distance of 2 cm. A single ground was secured to the tibia. After the electrode had been placed, participants were positioned supine on a padded table with a comfortable bend in their hip and knee. The upper leg was supported in the self-selected position with foam padding, and the foot was strapped to an adjustable pedal set to the participant's angle of maximal plantar flexion. The pedal was connected to a force transducer to measure force production throughout the study.
Fifteen minutes after the beverage had been consumed, participants performed a 5-s maximum voluntary isometric contraction (MVC) of the triceps surae muscles against the foot pedal to determine maximal force production and for data normalization purposes. After having performed this 5-s MVC, participants elicited EAMC by performing a sustained maximum isometric contraction of the triceps surae against the foot pedal until muscle cramp onset. Immediately after cramp onset, participants ceased voluntary contraction and remained motionless until the muscle cramp subsided. If 90 s of isometric contraction did not produce a cramp, contraction was halted, and, after a 10-min rest, the participant again attempted to produce a cramp. This pattern of 90-s contraction/10-min rest was repeated until either a muscle cramp occurred or the participant was unsuccessful at producing a cramp after 5 attempts.
Immediately after the cramp subsided, participants rated muscle soreness on a 1-10 (no soreness to extreme soreness) scale. The participant then performed a postcramp 5-s MVC to determine maximal force production after cramping. After a 20-min rest, a rating of residual soreness was obtained on the same 1-10 scale. Joint angles of the participant's lower limb were measured with a goniometer and recorded for identical repositioning on subsequent visits. Data Analysis. EMG data were measured on an IX-RA-834 recorder with attached iWire BIO8 and IX-BIO4 biopotential amplifiers (iWorx) and recorded, stored, and analyzed offline in LabScribe3 software (iWorx). Data were sampled at 1,000 samplesÁs 21 , bandpass filtered at 100 HZ-10 kHZ, rectified, and integrated with a time constant of 0.001 s to calculate area under the curve (AUC) during the precramp isometric contraction and muscle cramp. There was no between-treatment difference in maximum EMG signal (A, 0.59 6 0.04 lV; V, 0.55 6 0.04 lV; P 5 0.39); to account for slight differences in electrode placement between visits altering EMG signal intensity, all data were normalized to a percentage of maximum EMG signal (%EMG max ; greatest 1% of EMG values during MVC). Cramp onset was noted when participants first reported a cramp and was confirmed by visual inspection of the EMG signal and identified by quieting of the EMG signal in noncramping musculature but continued EMG activity in the cramping musculature. 24 Statistical Analysis. Results are reported as mean 6 SE. Student's t test for related samples (one tailed) was used to assess differences between A and V. Effect size (ES; Cohen's d), adjusted for correlation, is reported for mean differences. Interpretation of ES follows the convention of Cohen; 0.2, 0.5, and 0.8 correspond to ES of small, medium, and large, respectively. 25 Statistical analyses were performed in SPSS version 21 (IBM, Armonk, NY), with a 5% level of significance for all statistical tests. Participants. Participants were young, healthy, recreationally active, nonsmokers free of neurological disease. Participants in study 2 represented a unique participant sample from study 1 and were not required to have a history of EAMC.
Study Design. Participants came to the laboratory on 3 separate occasions, having refrained from vigorous exercise and from consuming caffeine or alcohol for 12 h. The first visit served as a familiarization trial to orient participants to the experimental setup and to minimize learning effects. Participants then completed 2 experimental trials; each trial was performed 15 min after ingesting either A or V in a randomized, counterbalanced order. Rigorous blinding of participants and investigators was performed as described for study 1. Experimental trials were separated by at least 24 h to allow for treatment washout.
Tests. Participants completed a simulated kinematic reaching task to evaluate upper extremity coordination by using an experimental virtual reality-based apparatus described elsewhere. 26, 27 Briefly, participants sat in a chair with arms supported against the effects of gravity and friction by air sleds. Participants faced an interactive 2-dimensional (2D) virtual workspace in which stimuli displayed on a 52-in. HDTV (Sony Electronics, Tokyo, Japan) were reflected onto a mirror that prevented visualization of the arms. The distance between the monitor and the parallel mirror was adjusted to give the illusion that the stimuli appeared in the plane of the fingertips.
A 6-degree-of-freedom (6-DOF) Flock of Birds tracking system (Ascension Technology, Shelburne, VT) was used to record the position and orientation of the limb segments at 116 HZ sampling rate. 6-DOF sensors were attached to the middle of each wrist and the middle of each upper arm.
The position of the tip of the index finger was recorded relative to the wrist sensor, and positions of the elbow and shoulder joints were recorded relative to the upper arm sensor. The 2D position of the tip of the index finger was used to project the cursor onto the mirror. Data were low-pass filtered with a 12-HZ zero-lag Butterworth filter prior to differentiating to yield velocity profiles. Outcome measures of interest were maximum velocity, final position error, and deviation from linearity.
Each participant was instructed to adjust display cursor location by moving the cursor from a starting point to a target as quickly and accurately as possible. Each target was individually determined based on participant limb segment length such that all participants reached for targets that required the same shoulder and elbow angles. Participants completed 60 trials (30 per arm) ; then, the same protocol was repeated without air sleds and with participants holding their arms up off the table to introduce the effects of gravity.
Participants then completed a series of standardized psychomotor tests to measure upper limb motor function and manual dexterity. Supporting Information Table 1 provides descriptions of the psychomotor tests and outcome measures as well as descriptions of the 3 outcome measures of interest for kinematics. All psychomotor tests that were used are reliable; all have been repeatedly validated and are commonly used in psychomotor research.
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Statistical Analysis. Results are reported as mean 6 SE. Student's t test for related samples (two tailed) was used to assess differences between A and V conditions. Statistical analyses were performed in SPSS version 21 (IBM), with a 5% level of significance for all statistical tests.
RESULTS

Study 1.
Sixty-four potential participants with selfreported histories of muscle cramps were initially screened. Nineteen were unsuccessful in producing a muscle cramp on visit 1 and did not participate further. Two others failed to cramp on visits 2 and 3, and 1 failed to cramp during visit 4. Three other participants withdrew from the study because of time constraints, resulting in 39 (15 men, 24 women) participants completing the entire 5-visit protocol. These participants were young (22 6 1 years) and had a normal body mass index (BMI; 24 6 1 kgÁm 22 ). Figure 1 shows a representative original EMG record during isometric muscle contraction and subsequent muscle cramp in 2 EMG leads. Results from study 1 are shown in Figure 2 as both mean 6 SE and individual responses. There was a significant difference in time to onset of muscle cramping between treatments, with a significantly longer time to cramp onset for A (A, 36.9 6 4.1 s; V, 27.8 6 3.1 s; P 5 0.003). The ES for this variable was large (0.70). There was no difference between treatments in the AUC for the EMG signal during precramp contraction (A, 299 6 48 %EMG max Ás; V, 277 6 46 %EMG max Ás; P 5 0.334), and the ES was small (0.10). There was a significant difference between treatments in the average force produced during the muscle contraction prior to cramp onset (A, 13.8 6 1.8 kg; V, 9.9 6 1.6 kg; P 5 0.002), with participants producing more force before cramping after consuming A (large ES, 0.72).
There was no difference between treatments for the duration that the cramp persisted (A, 14.8 6 2.2 s; V, 16.4 6 2.2 s; P 5 0.144), and the ES was small (0.24). The EMG AUC during the muscle cramp showed a significant difference between treatments (A, 37.3 6 7.2 %EMG max Ás; V, 77.2 6 17.7 %EMG max Ás; P 5 0.010), with a smaller cramp intensity-duration profile after participants consumed A (medium ES, 0.63).
There was a significant difference between treatments in the subjective rating of muscle soreness immediately postcramp (A, 4.1 6 0.3 a.u.; V, 4.7 6 0.3 a.u.; P 5 0.011), with reported soreness significantly lower after participants consumed A (medium ES, 0.55). There was no difference in the ratings of residual muscle soreness 20 min postcramp (A, 2.6 6 0.2 a.u.; V, 2.8 6 0.3 a.u; P 5 0.092; data not shown). There was no difference in the MVC force either before cramping (A, 13.5 6 1.5 kg; V, 13.2 6 1.6 kg; P 5 0.378) or after cramping (A, 12.9 6 1.6 kg; V, 12.6 6 1.3 kg; P 5 0.299; data not shown).
Study 2. Thirty-one participants (12 men, 19 women) were enrolled in and completed the motor function tests. Participants were young (23 6 3 years) and had a normal BMI (23 6 1 kgÁm -2 ). Results for study 2 are presented in Table 1 . There was no treatment effect on any of the kinematic or psychomotor tests.
DISCUSSION
We found that ingesting TRPV1 and TRPA1 channel activators positively improved several cramp-related features in our isometric cramp model, increasing the contraction time and force production prior to cramp initiation, decreasing the EMG time-intensity relation during cramping, and decreasing subjective ratings of muscle soreness immediately after cramp cessation. Conversely, we observed no effect of oral TRP channel activators on fine motor performance. Therefore, we conclude that ingestion of known oral and upper gastrointestinal mucosal TRP channel agonists attenuated the electrical characteristics of voluntary isometric cramps, suggesting benefits in exercise tolerance and performance in those who regularly experience EAMCs, without altering fine motor performance. This suggests that consumption of known TRP agonists would be beneficial for exercise performance in those who regularly experience EAMCs.
With the employed isometric cramp model, our 64% success rate (excluding dropouts) of inducing cramping is similar to previous studies of selfinduced muscle cramps. 24, 32, 33 We found that ingestion of A (relative to V) increased both the static muscle contraction time and the force required to produce a cramp; this has relevance for exercise activities because higher intensity or longer duration exercise could be achieved prior to muscle cramp onset. Despite the changes in duration and force, EMG activity prior to cramp onset remained the same between treatments, potentially because of the attenuated a-motor neuron hyperexcitability via TRP channel activation.
Cramp duration was not different between A and V; however, the EMG time-intensity relation (i.e., the AUC) during cramping was significantly reduced by A. Although high interindividual variability is expected, participants with the highest EMG AUC with V experienced the greatest reduction in this variable with A. This would suggest a greater efficacy for TRP agonists treating more intense muscle cramps compared with relatively benign cramps. This could be due to a different balance of local and neural factors contributing to the generation of cramps of varying intensities. Finally, postcramp muscle soreness was reduced with TRP agonist ingestion, likely the result of the reduction in muscle cramp intensity producing less residual discomfort.
Our data suggest that TRP channel activation may have dampened a-motor neuron hyperexcitability to mitigate cramping. However, we found that TRP agonist consumption did not affect small motor units (kinematic or psychomotor function), as evidenced by study 2. Because TRP agonists did influence cramping during study 1, it is possible that the TRP agonists target the large motor units. The central nervous system can control force with spatial recruitment or temporal recruitment. The results reported above indicate that the agonists influenced spatial recruitment by inhibiting a- motor unit activation to large motor units without a concurrent inhibition of smaller motor units. This is important for exercise and sport because cramping may be attenuated without hampering performance. These results are very promising for athletes and for those who experience muscle cramps during recreational activity. Although the differences between A and V in the variables measured were small, they were significant. All effects that we observed suggest that TRP agonist consumption attenuates muscle cramp characteristics because V was never superior to A. In an athletic setting, a small improvement may be enough to provide an advantage over an opponent or achieve a personal best. Overall, these results are encouraging and support TRP agonist consumption prior to exercise.
Although increasing evidence indicates that hyperactive motor neurons are the final mediator of EAMCs, putative triggers that may provoke that hyperactivity are many and varied. Dehydration, hyperthermia, low muscle glycogen, fatigue, muscle damage, and alterations in electrolyte concentration are among the putative triggers for EAMCs. Although the present data do not rule out these influences on EAMC, our participants were presumably euhydrated and in normal electrolyte balance, suggesting that disturbances in these parameters are not requisite for voluntarily induced cramp generation. Ingesting TRP channel agonists positively altered muscle cramp profiles, supporting the hypothesis that muscle cramps are neuromuscular in origin, regardless of the initiating environment or local milieu. Although TRP channel activation was not measured in this study, TRP channel activation is required for transduction of spicy sensations. Furthermore, Short et al. 22 empirically demonstrated that a blend of similar TRP agonists opens TRP channels.
TRPV1 and TRPA1 channels are involved in the transduction of spicy/hot tastes 10 and likely play a role in the mechanisms through which muscle cramps were mitigated in this study. It was therefore not possible to formulate a placebo with the same flavor profile as A. Consequently, we used the fluid base and flavoring without the TRP channel agonists for our blinded comparison. The use of a vehicle control beverage ensured that the only difference between trials was the presence or absence of TRP channel agonists. To circumvent the taste difference, participants were not informed about the A flavor profile. Furthermore, both beverages possessed strong flavor profiles (sweet/fruit vs. spicy), leading participants to assume that either (or both) beverages were designed to treat muscle cramping. Any placebo effect would require that participants be able to willfully and selectively control the activation of an isolated area of muscle in the midst of a painful muscle cramp, a highly unlikely scenario.
This study has certain limitations. We did not directly measure TRP channel activation. However, Short et al. 22 tested individual TRP channel agonists derived from biological extracts on ex vivo human dorsal root ganglia and found that these TRP channel agonists are capable of opening TRP channels. Our participants perceived the spicy flavor, sensory perception that occurs only with TRPV1 and TRPA1 channel activation. It is still possible that our findings are non-TRP channel mediated because TRP agonists exert other effects. For example, both TRPV1 and TRPA1 agonists can inhibit voltage-gated sodium channels, [34] [35] [36] which could be another avenue through which muscle cramping is attenuated. However, oral consumption of TRP agonists in the amount employed in this study does not significantly increase plasma concentration of these agonists, 37 supporting the assertion that the effects of TRP agonists are reflexive in nature.
The participants in our study were young, healthy, and recreationally active; results cannot be extrapolated to elite athletes or groups with pathology-associated muscle cramps, such as persons with amyotrophic laterals sclerosis (ALS), at this time. However, additional research in the ALS population is warranted because persons with ALS experience muscle cramps derived from motor neuron hyperexcitability, 38 making TRP agonist consumption a potential therapeutic modality. EAMCs were initiated via isometric muscle contraction. Studies using dynamic exercise models are required to confirm that our findings translate to real-world exercise.
Our voluntary cramp model inherently possessed greater variability than electrically induced models. We sought to decrease within-subject variability by having participants complete 3 familiarization trials. Because this voluntary isometric muscle contraction model was used only with rested, presumably euhydrated participants, the impact of varying levels of hydration and fatigue are unknown.
Finally, other TRP channel agonists, such as menthol, an agonist for TRP melastatin 8, have the potential to modulate motor unit activity. 20 It is not known whether oral ingestion of TRP agonists is the most effective means of delivery for attenuating EAMCs. Future research could examine other combinations of TRP agonists and pathways of administration.
In conclusion, in a group of young, healthy participants with a prior cramp history, ingestion of TRP channel agonists 15 min before testing positively altered EAMC characteristics. Conversely, there was no effect of consuming TRP channel activators on any aspect of kinematic or psychomotor measures of motor function mediated by smaller motor units. We conclude that consuming a beverage containing documented TRPV1 and TRPA1 channel activators mitigates self-induced muscle cramps but does not affect fine motor function.
